Request for Information for Cancer Medicines

Date of Request for Information (RFI): 22nd May 2026

Closing date for Request for Information (RFI): 12th June 2026

UNICEF Supply

UNICEF is a United Nations organisation that is committed to promoting the rights and wellbeing of all children worldwide. Together with our partners, we work in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere.

UNICEF Supply Division has its headquarters in Copenhagen Denmark.  Supplies are essential to fulfil children’s rights.  Supporting child survival and development programmes around the world, UNICEF-procured supplies are critical in providing for children’s health, education and protecting them from abuse, exploitation, and neglect.

In 2025, UNICEF procured US$5.677 billion worth of supplies and services for children in 164 countries and territories, including US$167 million in pharmaceuticals. In 2024, UNICEF procured US$5.610 billion worth of supplies and services in 160 countries and territories, including US$148.6 million in pharmaceuticals.

From 2025 till Q1 2026 UNICEF procured cancer medicines worth about US$ 8.09 million.

These figures provide general context on UNICEF procurement activity and are included for information purposes only.

Description of requirements:

Through this Request for Information, UNICEF seeks information from eligible suppliers on the availability of cancer medicines in order to inform market assessment, sourcing strategy and potential future procurement planning.

UNICEF is particularly interested in information on products that fall under one of the following regulatory pathways or oversight categories:

1. Products authorised by a regulatory authority recognised by WHO as a WHO Listed Authority (WLA) for the relevant product stream and regulatory function(s), such as registration and marketing authorisation and/or regulatory inspection. https://www.who.int/publications/m/item/list-of-who-listed-authorities-wlas
2. Products authorised by a non-WLA national regulatory authority and manufactured at a site that complies with applicable GMP requirements, as verified through inspection by a competent authority or through UNICEF’s own assessment, as applicable.
3. Products authorised by a national regulatory authority operating at WHO Maturity Level 3 (ML3) or ML4 for the relevant product stream, where applicable.
4. Other regulatory pathway or oversight category (please specify).

For an itemised list of products, please refer to accompanying Product Information Excel spreadsheet.

Potential suppliers: 

UNICEF purchases primarily direct from manufacturers and/or their authorised representatives. 

Procedure for submission of RFI:

Interested respondents are invited to complete the attached RFI form (word document) together with the RFI product information sheet (Excel format) and submit both documents to UNICEF by email to:

Ms Chinedum Ogbonna (cogbonna@unicef.org) no later than 12th June 2026

Include your company name in the subject of the email e.g. “Request for Information for cancer medicines – XXX Pharmaceuticals Ltd”

Please note:

• Pricing information is not requested at this stage.
• This RFI is issued for information-gathering and market assessment purposes only and does not constitute a solicitation, offer, or commitment by UNICEF to issue a solicitation or award a contract.
• UNICEF reserves the right, at its sole discretion, to amend, suspend, or discontinue this RFI and any related process at any time.

Thank you.